Rafa surges: Signs mega-contract of up to $257 million with U.S. military days after clinical trial success

Rafa Laboratories reports a strategic breakthrough with the signing of a framework agreement to supply auto-injectors to the U.S. Defense Logistics Agency (DLA). The achievement comes right after the company successfully completed a clinical trial for another product from the same

Rafa Laboratories signed an up-to-5-year framework agreement with the U.S. DLA to supply Midazolam auto-injectors, with a potential scope of up to $257 million. The company has already received an initial order of $9 million. The agreement comes just days after Rafa reported full success in a clinical trial for its Naloxone auto-injector, signaling strong momentum for the company in chemical defense.

Rafa Laboratories reported a strategic and commercial breakthrough with the signing of a framework agreement with the U.S. Defense Logistics Agency (DLA) to supply Midazolam auto-injectors. The agreement, for a term of up to five years, holds potential revenue of up to $257 million, positioning the Israeli company as a key supplier to the U.S. military. The dramatic announcement comes just days after the company reported full success in a clinical trial for another strategic product, a Naloxone auto-injector, marking a particularly successful week that solidifies its standing in the defense-medical market.

### Mega-deal with the Pentagon
According to the filing, the agreement with the DLA was signed on September 22 and includes a base year plus four option years. It is for the supply of 10mg Midazolam auto-injectors, used for rapid, immediate treatment in cases of exposure to nerve agent chemical warfare agents. It is a life-saving product intended to strengthen the U.S. military's readiness to address these threats.

The financial scope of the agreement underscores its importance: while the DLA's own estimate is for purchases totaling approximately $82.5 million over five years, the contract allows flexibility for purchases ranging from a minimum threshold of $47.5 million up to a potential ceiling of $257 million. In an initial sign of execution, Rafa has already received a preliminary order totaling approximately $9 million. This win represents a significant vote of confidence in Rafa's capabilities and opens a massive government market to the company.

### Dual momentum: Clinical and industrial success
The Midazolam contract win comes on the heels of a previous success reported by the company just days earlier: full compliance with all clinical trial endpoints for its 10mg Naloxone auto-injector. This product is designed for a different yet related scenario—treating exposure to chemical weapons containing ultra-potent opioid derivatives (such as fentanyl).

The clinical trial, conducted at the Ichilov Medical Center, demonstrated bioequivalence between Rafa's injector and the reference product from U.S.-based KALEO, which is currently the only FDA-approved product for this indication. The trial's success paves the way for Rafa to submit an FDA approval application via an expedited route (505(b)(2)), which allows reliance on the reference drug's data, thereby significantly shortening time-to-market. Successful approval would allow Rafa to break the existing monopoly in this market.

### Broader strategic picture
These two key events, occurring in close proximity, are no coincidence. They paint a picture of a focused, well-executed business strategy. Rafa identified a critical need in the global defense market for reliable auto-injectors and developed a product portfolio responding to various threats. Success in the Naloxone trial proves the company's R&D and regulatory capabilities, while the Midazolam contract win demonstrates its manufacturing capacity, quality, and ability to compete in and win some of the world's largest government tenders. For Rafa, this represents a strategic growth engine for years to come, securing revenue alongside significant potential to break into new markets.